To examine whether HBP1 is altered and associated with the clinical characteristics of the NSCLC patients, we first examined the protein expression level of HBP1 and β-catenin in 82 tumours from NSCLC patient by immunohistochemical analysis (Fig. 1A). Here, HBP1 is linked to non-small cell lung carcinoma.